Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275444 · ClinicalTrials.gov registry record · Phase 2
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
NCT00275444: Completed Phase 2 study, sponsored by Boehringer Ingelheim.
NCT00275444 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 216 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00275444, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
Study Summary
A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that achieves the best efficacy and safety as determined by evaluation of 2, 8, and 24-week virologic response and adverse event and laboratory profile measures would be selected for further clinical study.
Interventions
- DRUG Tipranavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2002-03-29 |
| Phase | Phase 2 |
What the finished NCT00275444 record still lists
NCT00275444 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 1 intervention - of which Tipranavir is the first listed.
NCT00275444 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00275444 about?
NCT00275444 is a clinical study titled "3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study". A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that achieves the best efficacy and safety as determined by evaluation of 2, 8, an...
What is the current status of trial NCT00275444?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2002-03-29.
What interventions are being tested in trial NCT00275444?
The interventions under investigation include: Tipranavir (DRUG).
Who is sponsoring clinical trial NCT00275444?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00275444's enrollment target sits among peer trials
216 286th of 2000 higher than 1,712 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI